https://scholars.lib.ntu.edu.tw/handle/123456789/568586
標題: | Dual chronic hepatitis B virus and hepatitis C virus infection | 作者: | CHUN-JEN LIU PEI-JER CHEN DING-SHINN CHEN |
公開日期: | 2009 | 出版社: | Springer New York | 卷: | 3 | 期: | 4 | 起(迄)頁: | 517-525 | 來源出版物: | Hepatology International | 摘要: | Dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are common in HBV or HCV endemic areas. However, several clinical and pathogenetic issues remain unresolved. First, clinical and in vitro studies suggest the interactions between two viruses. The dynamics of the interaction in untreated setting versus treated setting and its influence on the long-term outcomes await further studies. A key issue regarding viral interactions is whether modulation of infection occurs in the same dually infected individual hepatocyte of the liver. Clarifying this issue may help to understand the reciprocal interference between HCV and HBV and provide clues for future immunopathogenetic studies. Second, the prevalence and clinical significance of coexisting occult HBV infection in patients with chronic HCV infection need further investigations. Third, combination therapy of peginterferon alfa-2a and ribavirin appears to be just as effective and safe for the treatment of hepatitis B surface antigen (HBsAg)-positive patients chronically infected with active chronic hepatitis C as it is in patients with HCV monoinfection. Nevertheless, one-third of dually infected patients with nondetectable serum HBV DNA-level pretreatment developed HBV reactivation posttreatment. How to prevent and treat this reactivation should be clarified. Furthermore, about 10% of the dually infected patients lost HBsAg. Underlying mechanisms await further investigations. Finally, the optimal treatment strategies for dually infected patients with hepatitis B e antigen-positive chronic hepatitis B should be identified in future clinical trials. ? 2009 Asian Pacific Association for the Study of the Liver. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984588934&doi=10.1007%2fs12072-009-9147-9&partnerID=40&md5=9c9590b046cea0cb0b33768a993face7 https://scholars.lib.ntu.edu.tw/handle/123456789/568586 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-009-9147-9 | SDG/關鍵字: | alpha interferon; hepatitis B surface antigen; lamivudine; peginterferon alpha2a; peginterferon alpha2b; ribavirin; virus DNA; virus RNA; adaptive immunity; chronic hepatitis; clinical trial; drug efficacy; drug safety; geographic distribution; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; immunopathogenesis; incidence; innate immunity; mixed infection; nonhuman; prevalence; priority journal; review; seroconversion; treatment duration; treatment outcome; virus cell interaction; virus reactivation; virus replication |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。